Highest-materiality recent filing
Tevogen Bio receives Nasdaq deficiency notices for market value requirements
Nasdaq notified Tevogen on Apr 16, 2026 it fails $50M minimum market value for listed securities (MVLS).
Tevogen Bio regains Nasdaq minimum bid price compliance after reverse split
Received Nasdaq notice on March 20, 2026 confirming compliance with Listing Rule 5450(a)(1).
Reverse stock split ratio 1-for-50; effective 12:01 a.m. March 6, 2026.
Tevogen Bio shareholders approve 100M share increase and reverse stock split authorization
Shareholders approved amending 2024 Omnibus Incentive Plan to add 100,000,000 shares, effective Feb 19, 2026.
Tevogen Bio board to evaluate potential one-time special cash dividend after unspecified milestones
Board intends to evaluate a special cash dividend contingent on future financial milestones (revenue, earnings targets).
Tevogen Bio gets Nasdaq deficiency notice; must regain $1.00 bid by March 2026
Received letter on September 23, 2025 from Nasdaq Staff for non-compliance with $1.00 minimum bid price rule.
Tevogen Bio grants 8M restricted shares to CEO; total outstanding 193.7M shares
Board approved restricted stock awards on June 27, 2025, including 8M shares to CEO Dr. Ryan Saadi.
Tevogen Bio enters $50M at-the-market equity sales agreement with A.G.P.
Sales agreement allows issuance and sale of up to $50M of common stock from time to time.
CEO Ryan Saadi contributes $500,000 to Tevogen Bio for new HQ costs
Founder and CEO Ryan Saadi contributed $500,000 cash to Tevogen Bio on June 30, 2025.
Stockholders elect Feike and Patton as Class I directors; ratify KPMG as auditor.
Jeffrey Feike received 150,304,146 votes for and 652,203 against; Dr. Curtis Patton: 150,313,660 for, 647,811 against.
Tevogen Bio doubles HQ leased space to 13,242 RSF; lease extended to Feb 2033
Lease amendment doubles space from 6,708 to 13,242 rentable square feet on Building's 2nd floor.
Tevogen Bio amends Bylaws to modify director resignation procedure for majority vote failures
Board amended Bylaws on April 21, 2025 to alter process for director resignations when director fails to receive majority vote in uncontested election.
Tevogen Bio inks related-party facility deal with CD8 for cell therapy production
Agreement with CD8 Technology Services (associated with >5% holder Dr. Manmohan Patel) for turn-key GMP cell therapy production facility.
Tevogen Bio receives $2M grant from KRHP LLC; up to $10M non-dilutive funding
Initial $2M grant from KRHP LLC; additional $8M contingent on KRHP's review of activities.
Tevogen Bio raises $6M via Series C Preferred Stock; two closings Aug 30 & Sept 16
Investor to purchase 600 shares of Series C Preferred Stock for $6.0 million aggregate.
Tevogen Bio raises $6M via Series C Preferred; director Suren Ajjarapu resigns
Sold 600 shares of Series C Preferred at $10,000 each for $6.0M aggregate to The Patel Family, LLP.
Tevogen Bio receives Nasdaq bid price deficiency notice, repurchases Series B Preferred Stock
Received Nasdaq letter on June 14, 2024, for non-compliance with $1.00 minimum bid price rule for 35 consecutive business days.
Tevogen Bio secures $36M unsecured credit line from 5% owner Patel Family; equity-linked terms
Loan agreement with The Patel Family LLP (affiliate of 5% holder Manmohan Patel) for up to $36M unsecured facility.
Tevogen Bio Inc reports 2023 net loss of $60.5M; cash only $1.05M, going concern raised
Net loss of $60.5M in 2023 ($2.44/share) vs $22.0M in 2022; no revenue.
Tevogen Bio enters $36M line of credit with Patel Family; also grants PIPE option for $14M+
Line of credit up to $36M, draws limited to $1M per month; interest lower of SOFR+2% or 7%.
Tevogen Bio Holdings appoints KPMG as auditor, dismisses Marcum
Audit committee appointed KPMG as independent auditor for FY2024, effective immediately.
Tevogen Bio's audited FY2023 shows $60.5M net loss, going concern doubt
Net loss of $60.5M in 2023 vs $22.0M in 2022; accumulated deficit $99.7M.
Expects to report $94.9M liability elimination from conversion of promissory notes into common stock.
Tevogen Bio raises $6.0M via Series A-1 Preferred Stock sale to existing investor
Sold 600 shares of Series A-1 Preferred at $10,000/share to Patel Family, LLP, affiliated with >5% holder Dr. Manmohan Patel.
Sold 600 shares Series A-1 Preferred Stock at $10,000/share for aggregate $6.0M to The Patel Family, LLP.
Tevogen Bio issues Series A and Series B Preferred Stock to raise $8M and settle ~$3.6M liabilities
Created Series A Preferred Stock sold to Dr. Manmohan Patel for $8M ($4,000 per share), cumulative 5% annual dividend rising 2% yearly.
Tevogen Bio adopts Code of Business Conduct and Ethics on Feb 14, 2024
Company adopted a Code of Business Conduct and Ethics effective February 14, 2024.
Tevogen Bio raises $8M via Series A Preferred, assumes >$4.2M liabilities via Series B Preferred
Series A Preferred raised $8M in two installments ($2M due Feb 15, $6M by Mar 16); convertible into 2M shares.
Tevogen Bio completes SPAC merger valued at $1.2B, shares trade under LGST
CEO Ryan Saadi owns 72.3% of outstanding shares (118.35M of 163.75M) after business combination.
Semper Paratus shareholders approve merger with Tevogen Bio; redemptions ~$15.9M
Shareholders approved all proposals, including business combination, domestication, and charter changes.
Semper Paratus shifts combined Tevogen Bio listing target to Nasdaq from NYSE American
Parties agreed to seek Nasdaq listing for New Tevogen common stock and public warrants instead of NYSE American.
SEC declared effective the Form S-4 for the business combination between Semper Paratus (LGST) and Tevogen Bio.
Semper Paratus shareholders approve extension to Sep 2024; $9.7M redeemed
Shareholders approved extension of deadline to September 15, 2024 via one 3-month and six 1-month extensions.
SPAC Semper Paratus extends deadline to Sept 2024; $9.7M redeemed
Shareholders approved Extension Amendment allowing up to 9-month extension to Sept 15, 2024.
Semper Paratus furnishes investor presentation for proposed Tevogen Bio merger
Presentation provides additional detail on June 28, 2023 merger agreement between SPAC and Tevogen Bio.
Semper Paratus regains Nasdaq MVLS compliance effective Sept 28, 2023
Company received Nasdaq letter Sept 28, 2023 confirming regained compliance with MVLS Rule (minimum $50M market value).
Semper Paratus files S-4 for merger with Tevogen Bio; expects close near end of 2023
Filed Registration Statement on Form S-4 with SEC for proposed business combination with Tevogen Bio.
Semper Paratus Acquisition Corp. enters definitive merger with Tevogen Bio at $1.2B enterprise value
Merger consideration: $1.2B in Semper Paratus Class A common stock; plus up to 20M earnout shares at price targets of $15, $17.50, $20.
Semper Paratus Acquisition Corp. completes sponsor change; entire board and officers replaced
New Sponsor SSVK Associates purchased 7,988,889 Class A shares and 1,000,000 private placement units for $1.00.
SPAC Semper Paratus enters subscription and purchase agreements; cures Nasdaq delinquency
Subscription Agreement with Polar Multi-Strategy Master Fund for $151k capital; SPAC will issue 151k Class A shares at de-SPAC close.
Semper Paratus gets Nasdaq deficiency notice for MVLS below $50M
Nasdaq notified Semper Paratus on April 4, 2023, that its MVLS fell below $50M, violating Listing Rule 5450(b)(2)(A).
Semper Paratus receives Nasdaq delisting notice for unpaid fees of $151,000
Notice received March 23, 2023 for failure to pay $151,000 in Nasdaq listing fees.
Semper Paratus extends BC deadline to Dec 2023; $332M redeemed, trust reduced to $25M
Shareholders approved charter amendment extending business combination deadline from Feb 8, 2023 to Dec 15, 2023.
Semper Paratus initial shareholders convert all Class B shares to Class A
11,983,333 Class B Founder Shares converted to Class A shares on a one-for-one basis.
Semper Paratus corrects trust account amount in proxy; per-share value $10.34 as of Dec 31, 2022
Corrects typographical error: trust account per-share value is $10.34 as of Dec 31, 2022, up from $10.20 as of Sep 30, 2022.
CFO Philippe Kurzweil resigns; President Jeff Rogers appointed CFO and Secretary
Philippe J. Kurzweil resigned as CFO and Secretary, effective April 13, 2022.
Holders of 34,500,000 IPO units may elect to separate into Class A ordinary shares and warrants effective Jan 3, 2022.
Semper Paratus Acquisition Corporation closes IPO and private placement, raises $359.5M gross
IPO of 34.5M units at $10/unit raised $345M gross; private placement of 1.45M units raised $14.5M.
Semper Paratus closes $345M SPAC IPO; $351.9M placed in trust
Closed IPO of 34.5M units at $10.00 each, including full exercise of 4.5M-unit over-allotment.
On August 20, 2024, Suren Ajjarapu gave notice of his resignation from service as a director of the Company, effective August 21, 2024.
Susan Podlogar 60 Director Nominee
Jeffrey Feike 73 Director Nominee
Dr. Curtis Patton 88 Director Nominee
Kirti Desai 67 Chief Financial Officer
Surendra Ajjarapu 53 Director Nominee
Dr. Keow Lin Goh 52 Director Nominee
Victor Sordillo 71 Director Nominee
Dr. Neal Flomenberg 70 Chief Scientific Officer and Global R&D Lead
Dr. Ryan Saadi 59 Chief Executive Officer, Chairperson and Director Nominee
Sadiq Khan 62 Chief Commercial Officer
Richard N. Peretz, Hooman Yazhari, Paul P. Jebely, Brad Stewart, and Parizad Olver Parchi (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company
Max materiality 0.90 · Median 0.60 · Most common event other_material